Sign In
Buy CRDF
$1.40
-0.110 (-7.28%)
At Close: Jun 03, 2026
Cardiff Oncology (NASDAQ:CRDF) Stock Rating Lowered by Zacks Investment Research
07:06am, Sunday, 14'th Nov 2021 Dakota Financial News
Zacks Investment Research downgraded shares of Cardiff Oncology (NASDAQ:CRDF) from a hold rating to a sell rating in a research report sent to investors on Wednesday, Zacks.com reports. According to Zacks, Cardiff Oncology Inc. is a clinical-stage biotechnology company. It engages in developing treatment for cancer patients. The companys product pipeline consists of a Phase []
Cardiff Oncology (CRDF) Reports Q3 Loss, Tops Revenue Estimates
10:06pm, Thursday, 04'th Nov 2021
Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 0.00% and 43.33%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Cardiff Oncology (CRDF) Stock Jumps 7%: Will It Continue to Soar?
09:10am, Tuesday, 14'th Sep 2021
Cardiff Oncology (CRDF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength dow
Why Shares of Cardiff Oncology Rose on Monday
09:00pm, Monday, 13'th Sep 2021
An insider buy and positive data may have boosted optimism.
Why Are Investors Cheering Cardiff Oncology's New Data In Colorectal Cancer Setting?
06:27am, Thursday, 09'th Sep 2021
Cardiff Oncology Inc (NASDAQ: CRDF) has announced new data from Phase 1b/2 evaluating onvansertib in combination with standard-of-care (SOC) FOLFIRI/bevacizumab for second-line KRAS-mutated metasta
Cardiff Oncology to Present New Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer on September 8, 2021
08:15am, Wednesday, 25'th Aug 2021
SAN DIEGO, Aug. 25, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indication
Cardiff Oncology Reports Second Quarter 2021 Results and Provides Business Updates
04:15pm, Thursday, 05'th Aug 2021
SAN DIEGO, Aug. 5, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indicatio
Cardiff Oncology to Participate in a Fireside Chat at the William Blair Biotech Focus Conference 2021
08:30am, Tuesday, 06'th Jul 2021
SAN DIEGO, July 6, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical needs for new
Oncology Space Gains Momentum in 2021: 5 Stocks to Focus on
09:01am, Friday, 02'nd Jul 2021
Oncology stocks like OncoCyte (OCX), PerkinElmer (PKI), Catalent (CTLT), Cardiff Oncology (CRDF) and NovoCure (NVCR) are expected to continue their run over the next few months.
Cardiff Oncology Added to the Russell 2000® and other FTSE Russell Indexes
08:30am, Monday, 28'th Jun 2021
SAN DIEGO, June 28, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical needs for new
Cardiff Oncology: Current Slump Doesn't Look Right
10:12am, Monday, 14'th Jun 2021
CRDF fell on January data from CRC trial. However, the market had reacted more positively to its CRPC data.
Smoked! How the Hottest Cannabis Stocks Fared This Week
09:55am, Friday, 11'th Jun 2021
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead to how the cannabis industry continue
Cardiff Oncology Announces the Appointment of Two New Independent Members to its Board of Directors
12:30pm, Thursday, 10'th Jun 2021
SAN DIEGO, June 10, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical needs for new
SAN DIEGO, June 8, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical needs for new
Are Options Traders Betting on a Big Move in Cardiff Oncology (CRDF) Stock?
09:47am, Monday, 24'th May 2021
Investors need to pay close attention to Cardiff Oncology (CRDF) stock based on the movements in the options market lately.
